Project 467234

Most patients who have pelvic radiotherapy (RT) as a treatment for cancer experience some degree of acute gastrointestinal (GI) and genitourinary (GU) toxicities. All patients must have access to well-coordinated, high-quality, multidisciplinary care. If physicians can anticipate, identify, and correctly manage symptoms, they can significantly improve patients' quality of life (QoL). In our study, All patients receiving standard or hypo-fractionated curative pelvic RT at McGill University Health Centre Radiation Oncology clinic between January 2022 to September 2022 are eligible. The standard treatment duration is three to five weeks. Patients will complete, through a mobile application (Opal) and in real-time, electronic patient-reported outcomes (PROs) questionnaires about acute GI/GU toxicities and quality of life (QoL). These questionnaires will be administered at baseline, weekly during RT, and at three subsequent time points. The treating physician will fill in the traditional intra-treatment forms simultaneously. We will assess the association between PROs and clinician reported outcomes (CROs) over time using Somers D statistic, Bowkers Symmetry test, and multilevel random effects regression models. This study aims to evaluate the feasibility of collecting PROs and CROs for GI/GU toxicities prospectively and in real-time in a busy tertiary care cancer center, explore influence of baseline characteristics on treatment-related toxicity and determine the ability to use PROs to triage patient symptoms by correlating PROs/CROs evolution of scores with management changes (changes in medications, ER visits, hospital admissions). To the best of our knowledge, no available prospective study has addressed these questions, and prominent gaps in the literature remain.